Yep starting to see that also Hingdog.
BTX 1503 lesion count reduction: 47% (Market cap 53 million).
Aczone lesion count reduction: 38% (Market cap $456 million).
Epidui lesion count reduction: 42% (Market cap $494 million).
You think that may have something to do with it mate?
Oh, did you say BOT also caters for Atopic dermatitis and psoriasis?
The market will wake up soon enough.
Ann: Ethics Approval for Phase 2 Atopic Dermatitis Study Received, page-100
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.005(1.59%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $1.169M | 3.655M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 274982 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 48600 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
